Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H0Y0

UPID:
ATG10_HUMAN

ALTERNATIVE NAMES:
Autophagy-related protein 10

ALTERNATIVE UPACC:
Q9H0Y0; B2RE09; Q6PIX1; Q9H842

BACKGROUND:
The Ubiquitin-like-conjugating enzyme ATG10, alternatively named Autophagy-related protein 10, is integral to the autophagic process, acting as an E2-like enzyme. It specifically catalyzes the conjugation of ATG12 to ATG5, a necessary step for autophagy to occur. Unlike other enzymes, ATG10 is not involved in the conjugation of ATG12 to ATG3, underscoring its unique role in the autophagy pathway.

THERAPEUTIC SIGNIFICANCE:
The exploration of Ubiquitin-like-conjugating enzyme ATG10's function offers a promising avenue for developing new therapeutic approaches. Given its critical role in autophagy, targeting ATG10 could provide innovative treatments for conditions where autophagy modulation is beneficial.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.